Cargando…
Author Correction: Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer
Autores principales: | Hao, Xiang-lin, Gao, Li-yun, Deng, Xiao-juan, Han, Fei, Chen, Hong-qiang, Jiang, Xiao, Liu, Wen-bin, Wang, Dan-dan, Chen, Jian-ping, Cui, Zhi-hong, Ao, Lin, Cao, Jia, Liu, Jin-yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591344/ https://www.ncbi.nlm.nih.gov/pubmed/31235687 http://dx.doi.org/10.1038/s41419-019-1726-7 |
Ejemplares similares
-
Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer
por: Hao, Xiang-lin, et al.
Publicado: (2019) -
TC2N, a novel oncogene, accelerates tumor progression by suppressing p53 signaling pathway in lung cancer
por: Hao, Xiang-lin, et al.
Publicado: (2018) -
Enhanced Antitumor Efficacy of Gemcitabine by Evodiamine on Pancreatic Cancer via Regulating PI3K/Akt Pathway
por: Wei, Wei-Tian, et al.
Publicado: (2011) -
MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K/Akt signaling
por: Shen, Qiushuo, et al.
Publicado: (2022) -
SKA3 promotes lung adenocarcinoma metastasis through the EGFR–PI3K–Akt axis
por: Hu, Dan-dan, et al.
Publicado: (2020)